ADORA2A and Alzheimer disease: In our opinion, the results in this paper plus the literature data on neuroprotection by targeting the A2AR (see [29,51] for review) reinforces the hypothesis that A2AR antagonists could modulate glutamatergic action in AD and afford neuroprotection.